期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗凝新药研究进展 被引量：3

下载PDF
导出
摘要 动静脉血栓形成是许多心血管疾病的发病基础，是造成死亡的主要原因之一，近年来需要进行抗凝治疗的患者数量正在不断增加。目前临床上常用的抗凝药物主要有3类：维生素K拮抗剂、普通肝素和低分子肝素。维生素K拮抗剂华法林存在很多局限性，如起效缓、安全窗窄、受饮食影响、频繁的国际标准化比值（INR）监测及剂量调节、与多种药物之间存在相互作用等。低分子肝素虽然优于肝素，
作者 陈翔 秦永文
机构地区 上海第二军医大学附属长海医院心内科
出处 《中国心血管杂志》 2011年第5期386-389,共4页 Chinese Journal of Cardiovascular Medicine
关键词 抗凝治疗 维生素K拮抗剂 低分子肝素 动静脉血栓形成 国际标准化比值 新药 抗凝药物 心血管疾病
分类号 R54 [医药卫生—心血管疾病]
  • 相关文献

参考文献23

  • 1Beaglehole R, Bonita R. Global public health: a scorecald. Lancet, 2008,372 : 1988 -1996.
  • 2Ellis DJ, Usman MH, Milner PG, et al. The first evaluation of a novel vitamin K antagonist, tecarfarin ( ATI-5923 ) , in patients with atrial fibrillation. 2009,120 : 1029-1035.
  • 3Sanford M, Plosker GL. Dabigatran etexilate. Drugs, 2008, 68: 1699-1709.
  • 4Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmaeodynamies and tolerability of dabigatran etexilate, a new oral direct thrombin inhibit or, in healthy male subjects. Br J Clin Pharmacol, 2007,64 : 292-303.
  • 5Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Chn Phar macokinet ,2008,47:47-59.
  • 6Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus arfarin in patients with trial fibrillation. N Engl J Med ,2009,361 :2673-2674.
  • 7Gregory Y, Lars H, Bertil O, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose- guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J,2009,30:2897-2907.
  • 8Olsson SB, Rasmussen LH, Tveit A, et al. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost, 2010,103:481-483.
  • 9Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor II a. Semin Thromb Haemost, 2008,34 : 39-57.
  • 10Buller HR, Cohen AT, Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med.2007 .357 ,1094-1104.

同被引文献36

  • 1Wan Gen Yang Zhang Wang Shi Ying Xu.A new method for determination of antithrombotic activity of egg white protein hydrolysate by microplate reader[J].Chinese Chemical Letters,2007,18(4):449-451. 被引量：15
  • 2Huisman MV, Klok FA. How I diagnose acute pulmonary embolisal EJ]. Blood,2013,121(22) :4438 -4443.
  • 3Soo Hoo GW. Overview and assessment of risk factors for pulmona- ry embolism[J]. Expert Rev Respir Med,2013,7(2) :171 -191.
  • 4Konstantinides S, Lankeit M. Pulmonary embolism hotline 2012. Recent and expected trials[ J]. Hamostaseologie ,2013,33 (1) :43 -50.
  • 5Tapson VF. Thrombolytic therapy in acute pulmonary embolism [J]. Curt Opin Cardiol,2012,27(6) :585 -591.
  • 6Konstantinides S, Goldhaber SZ. Pulmonary embolism:risk assess- ment and management [ J ]. Eur Heart J, 2012,33 ( 24 ) : 3014 - 3022.
  • 7Castillo C,Tapson VF. Right ventricular responses to massive and submassive pulmonary embolism [ J ]. Cardiol Clin, 2012,30 ( 2 ) : 233 - 241.
  • 8Nassiri N, Jain A, McPhee D, et el. Massive and submassive pul- monary embolism: experience with an algorithm for catheter - di- rected mechanical thrombectomy [ J ]. Ann Vasc Surg, 2012,26 (1) :18 -24.
  • 9Piazza G, Goldhaber SZ. Management of submassive pulmonary embolism [ J ]. Circulation,2010,122 ( 11 ) : 1124 - 1129.
  • 10Torbieki A, Perrier A, Konstantinides S, et el. Guidelines on the diagnosis and management of acute pulmonary embolism : the Task Force for the Diagnosis and Management of Acute Pulmonary Em- bolism of the European Society of Cardiology (ESC) [ J ]. Eur Heart J.2008.29( 18 ,2276 -2315.

引证文献3

二级引证文献13

中国心血管杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部